{"filing":{"accession_number":"0001193125-26-279803","cik":"0001177648","ticker":"ENTA","company_name":"ENANTA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"d133783d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526279803/d133783d8k.htm"},"events":[{"id":13301,"run_id":11805,"accession_number":"0001193125-26-279803","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"summary":"Enanta disclosed an adverse Federal Circuit court ruling affirming summary judgment that invalidated claims of U.S. Patent No. 11,358,953 in its patent infringement suit against Pfizer over Paxlovid. This is a material litigation outcome involving a major pharmaceutical competitor and a core patent asset, directly affecting the Company's ability to recover damages and enforce its intellectual property rights.","company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10405,"accession_number":"0001193125-26-279803","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"Enanta disclosed an adverse Federal Circuit court ruling affirming summary judgment that invalidated claims of U.S. Patent No. 11,358,953 in its patent infringement suit against Pfizer over Paxlovid. This is a material litigation outcome involving a major pharmaceutical competitor and a core patent asset, directly affecting the Company's ability to recover damages and enforce its intellectual property rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:29:37.089092+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10405,"accession_number":"0001193125-26-279803","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"Enanta disclosed an adverse Federal Circuit court ruling affirming summary judgment that invalidated claims of U.S. Patent No. 11,358,953 in its patent infringement suit against Pfizer over Paxlovid. This is a material litigation outcome involving a major pharmaceutical competitor and a core patent asset, directly affecting the Company's ability to recover damages and enforce its intellectual property rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:29:37.089092+00:00","company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","filing_date":"2026-06-23"}]}